SEC Form 4 · accession 0001562180-15-000528
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephen Kanes
Officer — Chief Medical Officer
Period of report
Jun 24, 2015
Accepted (ET)
Jun 25, 2015 · 12:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 24, 2015 | M | 6,000 | $0.45 | A | 52,948 | D | |
| Common StockF1,F2 | Jun 24, 2015 | S | 6,000 | $74.06 | D | 46,948 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $0.45 | Jun 24, 2015 | M | 6,000 | D | — | Jul 23, 2023 | Common Stock | 6,000 | 40,300 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- F2This transaction was executed in multiple trades at prices ranging from $74.00 USD to $74.58 USD. The price reported above reflects the weighted average sale price.
- F325% of this option vested on July 18, 2014, and the remainder vests in equal monthly installments thereafter over 36 months.